Jafron Biomedical Co Ltd
SZSE:300529
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
16.6
37.82
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Jafron Biomedical Co Ltd
Total Liabilities
Jafron Biomedical Co Ltd
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
J
|
Jafron Biomedical Co Ltd
SZSE:300529
|
Total Liabilities
¥2.4B
|
CAGR 3-Years
23%
|
CAGR 5-Years
48%
|
CAGR 10-Years
N/A
|
|
|
A
|
APT Medical Inc
SSE:688617
|
Total Liabilities
¥665.8m
|
CAGR 3-Years
73%
|
CAGR 5-Years
64%
|
CAGR 10-Years
N/A
|
|
|
J
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
|
Total Liabilities
¥3.5B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
20%
|
CAGR 10-Years
24%
|
|
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
Total Liabilities
¥21.8B
|
CAGR 3-Years
30%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
L
|
Lepu Medical Technology Beijing Co Ltd
SZSE:300003
|
Total Liabilities
¥9.4B
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
39%
|
|
|
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
|
Total Liabilities
¥6.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Jafron Biomedical Co Ltd
Glance View
In the heart of China's bustling Guangdong province, Jafron Biomedical Co., Ltd. has carved a distinguished niche in the world of biomedicine since its inception. This innovative company, recognized as a leader in the hemoperfusion field, has built its reputation on a foundation of pioneering blood purification technologies. By developing and manufacturing an array of hemoperfusion devices, Jafron offers critical solutions that aid in the removal of toxins from the bloodstream, thus improving outcomes for patients suffering from various systemic toxic reactions and kidney-related disorders. Their state-of-the-art hemoperfusion cartridges, meticulously designed for efficiency, are instrumental in managing and treating conditions such as chronic kidney disease and liver dysfunction. This relentless pursuit of quality is bolstered by a dedicated research division that harmonizes clinical insights with scientific innovation, ensuring Jafron stays at the forefront of clinical demand. Jafron Biomedical thrives on a robust business model that fuses direct sales with an expansive network of partnerships. This dual approach not only amplifies their market reach but also enables the company to establish solid footholds in key domestic and international markets. By collaborating with healthcare institutions and medical device distributors, Jafron ensures its products deliver critical health solutions to a broad clientele. The revenue streams are mainly anchored in the sales of its hemoperfusion products and through strategic expansions in emerging markets. As global health standards evolve and the demand for advanced medical solutions expands, Jafron is positioned to sustain its growth momentum by continually innovating in response to the global demand for efficient blood purification therapies. Through these methods, Jafron not only augments its economic footprint but also underscores its commitment to enhancing global healthcare standards.
See Also
What is Jafron Biomedical Co Ltd's Total Liabilities?
Total Liabilities
2.4B
CNY
Based on the financial report for Sep 30, 2024, Jafron Biomedical Co Ltd's Total Liabilities amounts to 2.4B CNY.
What is Jafron Biomedical Co Ltd's Total Liabilities growth rate?
Total Liabilities CAGR 5Y
48%
Over the last year, the Total Liabilities growth was 1%. The average annual Total Liabilities growth rates for Jafron Biomedical Co Ltd have been 23% over the past three years , 48% over the past five years .
You don't have any saved screeners yet
